Academician Tang Zhaoyou (汤钊猷) - Pioneer of Liver Cancer Surgery & Hepatic Oncology at Zhongshan Hospital, Shanghai

About Academician Tang Zhaoyou

Academician Tang Zhaoyou (汤钊猷) is Professor, Doctoral Supervisor, Academician of the Chinese Academy of Engineering, and one of the most celebrated and historically significant figures in the global history of liver cancer surgery and hepatic oncology. Based at Zhongshan Hospital, Fudan University — one of China's premier academic medical centers and the institution where he spent his entire career building one of the world's largest and most influential liver cancer programs — Academician Tang is internationally recognized as the founding father of modern liver cancer surgery in China, the originator of the concept of subclinical hepatocellular carcinoma (HCC) and its surgical cure, and the scientist whose decades of clinical and translational research transformed the understanding and treatment of liver cancer worldwide.

The story of liver cancer surgery in China is inseparable from the story of Academician Tang Zhaoyou. When he began his career at Zhongshan Hospital in the 1950s, hepatocellular carcinoma was considered a uniformly fatal diagnosis — patients typically presented with advanced, symptomatic disease and died within months. Surgical resection was rarely attempted and almost never curative. Academician Tang's insight — that liver cancer could be cured if detected and resected at an early, subclinical stage before symptoms developed — led him to develop and champion alpha-fetoprotein (AFP) screening programs for high-risk populations in China, enabling the detection of small, asymptomatic HCCs that were amenable to curative resection. This concept of subclinical HCC and its surgical cure, developed and validated at Zhongshan Hospital over decades and thousands of patients, is now the foundation of international HCC surveillance guidelines and has directly saved hundreds of thousands of lives worldwide.

Academician Tang's contributions to liver cancer extend far beyond early detection. His research program at Zhongshan Hospital produced foundational insights into the biology of HCC recurrence and metastasis, the mechanisms of portal vein tumor thrombus formation, the role of the tumor microenvironment in HCC progression, and the development of multimodal treatment strategies — combining surgery, transarterial chemoembolization (TACE), ablation, and systemic therapy — that have shaped international HCC treatment guidelines. His concept of "residual cancer" — the idea that the key challenge in HCC treatment is not the primary tumor but the prevention and management of recurrence — has been profoundly influential in shaping the research agenda of the global HCC community.

While Academician Tang has largely transitioned from active surgical practice given his advanced age, his legacy is embodied in the world-class liver cancer program at Zhongshan Hospital — now led by his successors including Academician Fan Jia — and consultations arranged through CMCS connect international patients with the program he built, the colleagues he trained, and the institutional expertise he created over six decades of dedicated work.

Hospital Affiliation: Zhongshan Hospital, Fudan University

Zhongshan Hospital (中山医院), affiliated with Fudan University, is one of Shanghai's most prestigious and historically significant academic medical centers and a global leader in hepatology, liver cancer surgery, and hepatobiliary medicine. The Liver Cancer Institute at Zhongshan Hospital — founded by Academician Tang Zhaoyou and now one of the world's largest and most experienced liver cancer programs — is a national key clinical specialty and a WHO Collaborating Center for Research on Liver Cancer. The institute manages a high volume of HCC cases annually, including patients with early, intermediate, and advanced disease, and offers the full spectrum of HCC treatment modalities including surgical resection, liver transplantation, TACE, ablation (radiofrequency, microwave, cryoablation), stereotactic body radiotherapy (SBRT), and systemic therapy with sorafenib, lenvatinib, atezolizumab-bevacizumab, and other approved and investigational agents.

The institute's research infrastructure includes a dedicated HCC biobank, a translational research laboratory focused on HCC recurrence and metastasis, and an active clinical trials program evaluating novel systemic therapies, immunotherapy combinations, and locoregional treatment strategies. The institute maintains research collaborations with liver cancer centers at MD Anderson, Memorial Sloan Kettering, the University of Barcelona, and leading Asian institutions, and is consistently ranked as one of the top liver cancer programs in the world.

The Tang Zhaoyou Legacy: What It Means for International Patients

• Early hepatocellular carcinoma (HCC) — Zhongshan Hospital's Liver Cancer Institute, built on Academician Tang's concept of subclinical HCC and AFP-based surveillance, has the world's largest experience with the surgical resection of small, early-stage HCC. For patients with early HCC detected on surveillance, the institute's surgical outcomes — including long-term survival rates and recurrence-free survival — are among the best documented in the world literature
• Intermediate and advanced HCC — TACE; combination TACE with ablation or systemic therapy; conversion therapy for initially unresectable HCC; portal vein tumor thrombus management; systemic therapy with sorafenib, lenvatinib, atezolizumab-bevacizumab, sintilimab-bevacizumab, and other approved agents; access to investigational agents through clinical trials
• HCC recurrence and metastasis — management of intrahepatic recurrence after prior resection or ablation; re-resection for recurrent HCC; salvage ablation; management of extrahepatic metastases; systemic therapy for recurrent disease; the institute's unmatched experience with HCC recurrence — the central clinical challenge identified by Academician Tang — is a particular strength
• Liver transplantation for HCC — evaluation for liver transplantation within and beyond Milan criteria; bridging therapy with TACE or ablation; coordination with Zhongshan Hospital's liver transplantation program; post-transplant HCC recurrence management
• Portal vein tumor thrombus (PVTT) — surgical resection with PVTT removal; TACE and radiotherapy for PVTT; systemic therapy combinations; the institute's experience with PVTT management is among the largest in the world
• Multidisciplinary HCC management — tumor board review integrating surgery, interventional radiology, radiation oncology, and medical oncology; individualized treatment planning based on tumor biology, liver function, and patient performance status; access to clinical trials of novel systemic therapies and immunotherapy combinations
• Expert second opinion — review of imaging, AFP and other biomarkers, pathology, and treatment records for patients with HCC who are seeking a second opinion on resectability, treatment strategy, or access to investigational therapies; written English-language second opinion reports available through CMCS

Academic Legacy & Global Recognition

Academician Tang Zhaoyou's scientific legacy is among the most celebrated in the history of Chinese medicine and global oncology. He has authored and co-authored more than 600 peer-reviewed publications in Chinese and international journals, including landmark contributions to Cancer, Annals of Surgery, Journal of Clinical Oncology, Hepatology, Journal of Hepatology, Gut, and Chinese Medical Journal. His research on subclinical HCC, AFP screening, HCC recurrence biology, and multimodal HCC treatment has been cited thousands of times and has directly shaped international HCC surveillance and treatment guidelines including those of the American Association for the Study of Liver Diseases (AASLD), the European Association for the Study of the Liver (EASL), and the Asian Pacific Association for the Study of the Liver (APASL).

Academician Tang has received virtually every major honor in Chinese and international medicine, including the Highest Science and Technology Award of China, the AASLD Distinguished Scientific Achievement Award, and honorary fellowships from multiple international medical societies. He is a foreign associate of the US National Academy of Sciences and has received honorary doctorates from multiple international universities. His election to the Chinese Academy of Engineering reflects the transformative impact of his research and clinical leadership on the management of liver cancer in China and globally.

Academician Tang has trained more than 200 liver surgery and hepatic oncology fellows and residents who now lead programs across China and internationally, and his intellectual legacy is embodied in the Liver Cancer Institute at Zhongshan Hospital — now one of the world's foremost liver cancer programs — and in the international HCC research community that his work helped to create and inspire.

Why International Patients Come to Zhongshan Hospital's Liver Cancer Institute

For international patients with hepatocellular carcinoma — whether early-stage disease amenable to curative resection, intermediate-stage disease requiring TACE or combination therapy, advanced disease with portal vein tumor thrombus, or recurrent HCC after prior treatment — Zhongshan Hospital's Liver Cancer Institute offers a combination of clinical experience, surgical expertise, multimodal treatment capability, and translational research integration that places it among the top two or three liver cancer programs in the world.

The institute's particular strengths — its unmatched experience with early HCC resection, its deep expertise in HCC recurrence management, its large-volume TACE and ablation program, and its active clinical trials program — make it an especially valuable resource for patients who have been told their HCC is unresectable, patients with recurrent HCC after prior treatment, and patients seeking access to investigational systemic therapies or novel combination strategies. Treatment costs at Zhongshan Hospital are substantially lower than equivalent care in Western healthcare systems, and the speed of access to specialist consultation, multidisciplinary tumor board review, and treatment initiation is typically far faster than in public healthcare systems abroad. CMCS has coordinated liver cancer consultations and treatment programs for patients from North America, Europe, Southeast Asia, and the Middle East through Zhongshan Hospital's Liver Cancer Institute.

What to Expect at Your Consultation

Consultations at Zhongshan Hospital's Liver Cancer Institute arranged through CMCS begin with a comprehensive review of all prior imaging — including multiphasic CT or MRI of the liver with contrast, chest CT, bone scan or PET-CT for staging, AFP and other tumor marker trends, liver function tests, viral hepatitis serology and viral load, and pathology reports if biopsy has been performed — as well as the patient's oncological history, prior treatment records, liver disease history, and performance status. CMCS will arrange certified translation of all medical records, imaging reports, and laboratory results in advance of the consultation.

The consulting hepatic oncologist will assess the tumor stage and resectability, evaluate liver function reserve, outline the recommended treatment strategy — including the role and sequencing of surgery, TACE, ablation, radiotherapy, and systemic therapy — with detailed rationale, and provide a realistic assessment of expected outcomes. A multidisciplinary tumor board review involving hepatobiliary surgery, interventional radiology, radiation oncology, and medical oncology will be coordinated as appropriate. A written English-language consultation summary is provided after every appointment, and CMCS will facilitate direct communication between Zhongshan Hospital's liver cancer team and the patient's home oncologist and hepatologist for continuity of care planning.

Book a Consultation Through CMCS

China Medical Concierge Shanghai (CMCS) provides comprehensive end-to-end support for international patients seeking liver cancer consultation at Zhongshan Hospital's Liver Cancer Institute — the program founded by Academician Tang Zhaoyou and now one of the world's foremost centers for hepatocellular carcinoma. Our services include priority consultation scheduling with the liver cancer team and multidisciplinary tumor board, certified medical record and imaging translation, pre-consultation oncological and imaging review by our clinical coordinators, surgical logistics and hospital admission coordination, visa and travel support, accommodation recommendations near Zhongshan Hospital, on-site interpretation throughout the consultation and treatment process, pharmacy and systemic therapy coordination, and ongoing follow-up coordination between Zhongshan Hospital's liver cancer team and the patient's home physicians after return.

📧 contract@medicalsh.com | 💬 WeChat: gezhanglao | 🌐 medicalsh.com